7:00 am Check-In & Morning Coffee
8:00 am Chair’s Opening Remarks
The Future of Precision Medicine Adoption: Establishing National & Global Trial & Testing Initiatives to Supporting Wider, Equitable Access
8:10 am Expanding Access to Precision Cancer Care with the Precision Cancer Consortium CGP Implementation Guide
- Advancing Access to Precision Oncology: The Precision Cancer Consortium developed The Pathway to Precision Cancer Care, a strategic and operational guide to help health systems embed comprehensive genomic profiling (CGP) into routine cancer care and expand patient access globally
- The Impact of Limited CGP Capacity: Without coordinated action, patients miss opportunities for accurate diagnosis, targeted therapies, and clinical trials; costs rise due to inefficiencies; results may be delayed or misinterpreted; and patients and families lack information for shared decision-making
- Clinical & Economic Value at Risk: Limited access to CGP constrains patient outcomes and prevents health systems from realizing the wider economic value that precision oncology can deliver beyond healthcare
- Practical, Adaptable Solutions: The freely available, interactive guide provides actionable steps, tools, and real world examples to help health systems initiate, scale, and strengthen CGP programs. This session highlights how it is being used to improve access to optimal treatments
8:30 am Session Reserved for Illumina
Presentation Details to be Announced
9:00 am Panel Discussion: Mobilizing Precision Cancer Care Through the Precision Cancer Consortium to Standardize Testing Pathways & Reduce Access Barriers
- How can multi‑company collaboration accelerate global access to comprehensive genomic profiling, particularly in regions where testing infrastructure and reimbursement remain limited?
- What operational barriers most constrain CGP adoption, and what tools can help standardize processes across health systems?
- How can harmonized testing pathways, shared training resources, and coordinated industry engagement reduce variation in CGP turnaround times and improve diagnostic quality globally?
9:20 am Session to be Confirmed
Inquire about remaining partnership opportunities at sponsor@hansonwade.com
9:50 am Session Reserved for GSK
Presentation Details to be Announced
10:20 am Morning Break & Refreshments
10:50 am One-to-One Meetings & Structured Networking
Biomarker Discovery & Translation
Clinical & CDx Development
Rx–Dx Commercialization & Adoption
Digital Pathology & Spatial Biomarkers
Multimodal & AI-Enabled Precision Medicine
Biomarker Discovery & Translation
Translating Early Biomarker Insights into Scalable Operations & Adaptive Validation for Precision Therapeutic Development
11:00 am Session Reserved for Genetron
Presentation Details to be Announced
11:30 am Planning Early for Downstream Biomarker & Laboratory Complexities in Clinical Trials
Director, Clinical Laboratory & Diagnostic Delivery, Regeneron
- Early biomarker and assay identification and development
- Considering global operations to ensure future agility
- Vendor engagement strategies to improve biomarker and diagnostic operational delivery
11:50 am Session to be Confirmed
Inquire about remaining partnership opportunities at sponsor@hansonwade.com
12:20 pm Advancing Precision Oncology: Developing Translational Biomarkers for a Novel Mitochondrial-Targeted Therapy
President & Chief Executive Officer, Bantam Pharmaceutical
- Therapeutic programs with novel targets and mechanisms of action present significant challenges when developing translational biomarkers to select patients and characterize treatment responses
- BTM-3566 modulates mitochondrial dynamics as a unique therapeutic strategy for treating tumors resistant to standard of care and those tumors with aggressive genomic profiles
- A summary of the scientific progression of this drug and the considerations for various biomarker strategies explored will be presented as well as current clinical study plans to develop a precision medicine product
Clinical & CDx Development
Rx–Dx Commercialization & Adoption
Digital Pathology & Spatial Biomarkers
Multimodal & AI-Enabled Precision Medicine
12:40 pm Lunch Break & Networking
1:30 pm One-to-One Meetings & Structured Networking
Integrating Companion Diagnostics Strategies into ADC Programs to Strengthen Patient Selection & Drive More Consistent, Durable Responses Across Diverse Tumor Profiles
1:40 pm Assessing Histologic Biomarkers of Response to Micvotabart Pelidotin (MICVO), the First-in-Class ADC Targeting the Tumor Extracellular Matrix Protein Extradomain-B of Fibronectin
- MICVO binds to extradomain-B of fibronectin (EDB+FN) in the tumor extracellular matrix where the linker is cleaved by extracellular cathepsins to allow free auristatin payload to diffuse into and kill cancer cells directly, via the bystander effect, and by eliciting immunogenic cell
- Pyxis Oncology developed an exploratory immunohistochemistry assay and scoring system to measure the intensity and distribution of EDB+FN in the extracellular matrix of the tumor stroma of preclinical and clinical samples
- Biological drivers, in addition to EDB+FN target expression, may confer sensitivity to MICVO, suggesting a multi factorial biomarker approach to understanding tumor responsiveness to treatment
2:00 pm Session Reserved for Labcorp
Presentation Details to be Announced
2:30 pm Deciphering Mechanisms of Resistance to ADC Therapy
- What is an optimal framework to define ADC mechanism of action?
- How does ADC mechanism of action inform potential evolution of resistance?
- What are key mechanisms of resistance and how do they impact future treatment strategies?